TY  - GEN
AU  - Muñoz,Delicias
AU  - Escartín,Antonio
AU  - Dapena,Dolores
AU  - Coret,Francisco
AU  - Fernández-Uría,Dionisio
AU  - Pérez,Domingo
AU  - Casanova,Bonaventura
AU  - Guijarro-Castro,Cristina
AU  - Munteis,Elvira
AU  - del-Campo Amigo,María
AU  - Pego,Robustiano
AU  - Calles,Carmen
AU  - García-Rey,César
AU  - Monsalve,Nuria
AU  - Sánchez-Matienzo,David
TI  - Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers
SN  - 1471-2377
PY  - 2013///1028
KW  - 2',5'-Oligoadenylate Synthetase
KW  - metabolism
KW  - Body Mass Index
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunologic Factors
KW  - adverse effects
KW  - Interferon-beta
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Multiple Sclerosis, Chronic Progressive
KW  - drug therapy
KW  - Neopterin
KW  - Predictive Value of Tests
KW  - Retrospective Studies
KW  - Treatment Outcome
KW  - beta 2-Microglobulin
N1  - Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1186/1471-2377-13-82
ER  -